Introduction {#s1}
============

Subchondral bone is an integral component of the joint, absorbing compressive forces during movement ([@bib50]). Physiological subchondral bone remodeling maintains its structural integrity and supports the overlying articular cartilage. Age or trauma ([@bib27]) related alteration of subchondral bone is a principal risk factor of osteoarthritis (OA), the most common joint disease ([@bib7]) characterized by cartilage destruction ([@bib24]; [@bib35]), subchondral sclerosis ([@bib64]) and synovitis ([@bib6]; [@bib60]). Pain, as the major symptom for OA patients ([@bib40]), often leads to physical disability and mortality in senior patients ([@bib14]). Although the major local source is not clearly defined ([@bib48]), there is evidence showing that synovitis ([@bib60]) and subchondral bone marrow lesion (BML) are highly relevant to OA pain. BML is a fluid enriched area under magnetic resonance imaging (MRI) and is characterized as bone marrow edema, fibrosis, microfractures or trabecular pattern alterations in pathological examinations, with high relevance to abnormal bone remodeling. However, how subchondral BML induces OA pain, still remains largely unknown. We previously showed that aberrant subchondral bone remodeling in response to altered mechanical loading patterns in OA was initiated by over-activation of transforming growth factor β1 (TGF-β1). High levels of subchondral TGF-β1 signaling induces mesenchymal stem cells (MSC) clustering and leads to the uncoupling of osteoblastic bone formation, osteoclastic bone resorption and angiogenesis. Moreover, we found overactivated osteoclasts in BML aggravated OA pain by secreting the axon guidance molecule Netrin-1 to induce subchondral sensory innervation ([@bib74]). The increased sensory innervation provides a structural base for the transmission of nociceptive signals from the subchondral bone to the central nervous system. However, how these nerve fibers are activated and sensitized during OA progression remains to be elucidated.

The persistent low grade of local inflammation is another hallmark of OA ([@bib53]; [@bib67]). During the uncoupled bone remodeling in OA progression, a series of pro-inflammatory factors ([@bib32]; [@bib60]) like prostaglandin E2 (PGE2) ([@bib15]), interleukin-1β (IL-1β), interleukin-6 (IL-6) are released into the subchondral bone area ([@bib51]). We previously showed that PGE2 was a crucial factor in both pain sensation and bone metabolism ([@bib67]). However, the main source remains largely unknown. We newly discovered a feedback mechanism on sensory nerve regulation of bone mass. PGE2 concentration is inversely related to bone mass and sensory nerves monitors bone density by responding to the concentration of PGE2 in bone ([@bib15]). We found that when bone mass is decreased, the enzymatic activity of cyclooxygenase 2 (*Cox2*) in osteoblastic lineage cells was significantly increased and thus catalyzes more arachidonic acid into PGE2. At the early stage of OA, the bone density is temporarily decreased, which resembles the low bone density as seen in osteoporosis. Currently, there is still lack of information whether the increased PGE2 in OA subchondral bone is also attributed to the increased *Cox2* activity in osteoblastic cells in response to low bone mass.

PGE2 functions as an inflammatory mediator and a neuromodulator that alters neuronal excitability ([@bib59]). In the four types of G-protein-coupled EP receptors (EP1-EP4) that mediate the functions of PGE2, EP4 receptor is considered as the primary mediator of PGE2- evoked inflammatory pain hypersensitivity and sensitization of sensory neurons ([@bib10]; [@bib13]; [@bib43]; [@bib52]; [@bib57]; [@bib62]; [@bib65]), as evidenced by that the specific EP4 receptor antagonists could reduce acute and chronic pain ([@bib57]), including OA pain ([@bib1]). Increased neuronal excitability contributes to the generation of hypersensitivity in various types of chronic pain ([@bib37]; [@bib48]). PGE2 has been shown to potentiate several ion channels in neurons to enhance neuronal excitability ([@bib23]). Voltage-gated sodium channel (Na~V~), a member of the tetrodotoxin-resistant sodium channel (TTX-R), is mainly expressed in small- and medium-sized Dorsal root ganglion (DRG) neurons and their fibers. The Na~V~ is responsible for initiating and propagating electrical signal transmission by inducing Na^+^ influx to start action potential firing. PGE2 has been shown to modulate the sodium current of the TTX-R in DRG neurons and promote Nav1.8 trafficking to the cell surface ([@bib21]; [@bib44]). Therefore, the PGE2 induced neuronal hypersensitivity is likely to be mediated by the Nav 1.8 during OA progression.

Among the 9 subtypes of Na~V~s (Na~V~1.1--1.9), Na~V~1.8 ([@bib2]) is the main drug target due to its highly relevant to pain signal transmission, and restricted distribution in primary nociceptive neurons ([@bib3]; [@bib30]). Gain of function mutations in human in the promoter region of Na~V~1.8 directly induces pain hypersensitivity ([@bib19]). Interestingly, animals lacking Na~V~1.8 display significant lower mechanical pain sensitivity with modest changes in heat or innocuous touch sensitivities ([@bib3]; [@bib5]). This specificity of Na~V~1.8 in transducing mechanical pain signals makes it highly possible in the participation of mechanical allodynia in OA. Moreover, post-transcriptional modifications of Na~V~1.8 including phosphorylation ([@bib26]; [@bib28]; [@bib71]) and methylglyoxalation ([@bib8]) further regulate its activity. A recent study demonstrated that inhibition of the expression of Na~V~s in nociceptive neurons was effective in OA pain alleviation ([@bib54]), with the detailed molecular mechanism remained to be clarified ([@bib63]).

In this study, we take the initiative to show that aberrant subchondral bone remodeling contributes to neuronal hypersensitivity during OA progression. Excessive PGE2 is synthesized by osteoblastic lineage cells in response to the low bone density at the early stage of OA. Excessive PGE2 sensitize sensory fibers innervates subchondral bone by upregulating the expression of sodium channel Na~V~1.8 in both subchondral bone nerve fibers and DRG neuron body, which contributes to peripheral mechanical allodynia during OA progression. Therefore, we developed a small molecule conjugate by linking the TGFβ type receptor 1 (Tβ1R) inhibitor (LY-2109761) and alendronate (Aln) ([@bib27]) to achieve bone-targeted delivery. We used this conjugate (Aln-Ly) as a proof of concept drug to test whether reversing the aberrant bone remodeling by synergistically inhibiting osteoclast bone resorption and the excessive TGF-β activity can substantially reduce the PGE2 production and subsequent mechanical hypersensitivity that generated in OA subchondral bone.

Results {#s2}
=======

Na~V~1.8 was modified in the subchondral bone and mediate OA progression {#s2-1}
------------------------------------------------------------------------

To identify the primary voltage-gated sodium channel in subchondral sensory fibers that responsible for mechanical hypersensitivity during OA progression, we tested the expression levels of different sensory related sodium channel Na~V~s in OA mice post anterior cruciate ligament transection (ACLT). The transcription levels of mRNAs that encode Na~V~s in DRG including Na~V~1.1, Na~V~1.2, Na~V~1.3, Na~V~1.6, Na~V~1.7, Na~V~1.8, Na~V~1.9 were measured by qPCR using mRNA isolated from mouse ipsilateral L3-5 DRGs one month post-ACLT or sham surgery. Compares to the sham-operated group, the expression of mRNA encoding Na~V~1.8 increased 2.5 folds in the ACLT group as the highest upregulation among all the Na~V~s. The mRNAs encoding Na~V~1.7 and Na~V~1.9 showed moderate upregulation in the ACLT group relative to that of the Sham group while the changes of Na~V~1.1 Na~V~1.2 Na~V~1.3 or Na~V~1.6 were not detected ([Figure 1a](#fig1){ref-type="fig"}). Therefore, we further investigated Na~V~1.8 protein expression in the immune-histological analysis of OA subchondral bone. The intensity of Na~V~1.8 immunofluorescence in subchondral bone was also elevated about 2 to 3 folds in OA mice compared to sham- operated mice one- or two-months post-surgery ([Figure 1b and c](#fig1){ref-type="fig"}). To examine whether the increase of Na~V~1.8 expression is limited to in a certain subtype(s) of the DRG neuron that innervates subchondral bone in OA mice, Na~V~1.8 was co-stained with different markers for sensory nerve subtypes based on the current classification of DRG neurons ([@bib68]). The expression rate of Na~V~1.8 in total nerve fibers (labeled by pan neuron marker PGP9.5) innervated in subchondral bone significantly increased post-ACLT ([Figure 1---figure supplement 1a,f](#fig1s1){ref-type="fig"}). Moreover, the elevated Na~V~1.8 expression was highly co-localized with the peptidergic nociceptor marked by calcitonin gene-related peptide (CGRP) ([@bib11]; [Figure 1---figure supplement 1b,f](#fig1s1){ref-type="fig"}) and mechanosensitive low-threshold mechanoceptors (labeled by PIEZO2) ([@bib20]). The expression of Na~V~1.8 was also slightly elevated in the synovium ([Figure 1---figure supplement 1f](#fig1s1){ref-type="fig"} 1 hr, j). Both western blot analysis ([Figure 1f](#fig1){ref-type="fig"}) and immunostaining ([Figure 1---figure supplement 1f](#fig1s1){ref-type="fig"} 1 g, i) of ipsilateral lumbar 3--5 DRG confirmed the upregulation of Na~V~1.8 expression at the DRG level. We then further validated whether DRG neurons with upregulated Na~V~1.8 expression directly innervates fibers in the subchondral bone. We injected a neurophilic fluorescent dye (DiI) into the subchondral bone to label the distal nerve fibers ([@bib22]). We found that the Na~V~1.8^+^ neurons labeled by DiI significantly increased in the DRG neurons of OA rats relative to sham-operated rats ([Figure 1g,h](#fig1){ref-type="fig"}), indicating that DiI was transported into DRG neurons by the sensory fibers innervated subchondral bone in a retrograde manner. These results suggest that the expression of pain-related sodium channel Na~V~1.8 is upregulated in DRG neurons and their axons that innervate subchondral bone during progression. We then examined the association between Na~V~1.8 neuronal activity and OA pain. Von Frey test showed that the hind paw withdrawal threshold (HPWT) dropped nearly 60% and maintained at this level throughout the two month-period post ACLT relative to the sham-operated group, suggesting that development of mechanical allodynia in OA mice ([Figure 1g](#fig1){ref-type="fig"}; [@bib14]). To assess the potential role of Na~V~1.8 in DRG neuronal excitability, we used an in vivo DRG imaging in Pirt^GCaMP3fl/-^mice that we recently developed. In this genetically targeted mice, genetic-encoded Ca^2+^ indicator GCaMP3 is specifically expressed in \>95% of all DRG neurons under the control of the Pirt promoter. In the Pirt^GCaMP3fl/-^mice, the excitability of the nociceptive neurons in DRG can be visualized by fluorescence signals of calcium influx. The number of excited DRG neurons ipsilateral to the surgery significantly increased in OA mice compared to sham-operated mice, and importantly, administration of Na~V~1.8 inhibitor (A-803467)([@bib29]) blunted the signal in DRG ([Figure 1h and i](#fig1){ref-type="fig"}). To validate the excitation of DRG neurons related to Na~V~1.8, we performed patch-clamp in the DRG neurons that were isolated from mice that underwent ACLT or sham surgery. The action potential number and Na~V~1.8 current density significantly elevated in ACLT mice relative to sham-operated mice, and the elevations were blocked by A-803467 ([Figure 1j--l](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1f](#fig1s1){ref-type="fig"} 1 k and l). Thus, the activation of Na~V~1.8 mediates OA pain related DRG neuron hypersensitivity.

![Nav1.8 modification after mice model of OA.\
(**a**) Heatmap of relative expression levels of Na~V~ channels in ipsilateral L3-L5 DRGs after sham or ACLT surgery. (**b, c**) Immunostaining of Na~V~1.8^+^ (green) nerve fibers (**b**) and statistical analysis (**c**) in mouse tibial subchondral bone after sham or ACLT surgery at 1 m and 2 m. Scale bars, 20 μm, n = 6 per group. (**d, e**) Immunostaining of Na~V~1.8^+^ (green) nerve fibers (**d**) and statistical analysis (**e**) in ipsilateral sciatic nerve after sham or ACLT surgery at 1 m. Scale bars, 40 μm, n = 6 per group. (**f**) Western blots of Na~V~1.8 in mouse ipsilateral L3-5 DRGs 1 month post sham or ACLT surgery. the experiment was repeated three times and a representative result was chosen. (**g, h**) Retrograde tracing of Nav1.8 (green) and DiI (red) and DAPI (blue) double-labeled neurons (**g**) and percentage of double labeled neurons (**h**) in ipsilateral L4 DRG of rat after sham or ACLT surgery in 3 m. Scale bar, 80 μm. n = 6 per group. \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 compared with the sham-operated group at different time points. Statistical significance was determined by multifactorial ANOVA WITH BONFERRONI POST HOC TEST (**c, k, l**), unpaired Student's *t* test (e an i) and all data are shown as scattered plots with means ± standard deviations. (**h, i**) Representative photomicrographs (**h**) and statistically analysis of activated neurons (**i**) in ipsilateral L4 DRG using in vivo Pirt-GCaMP3 imaging treated before or after A803467 1 month post sham or ACLT surgery. n = 6 per group. (**j--l**) Representative traces of Aps (j upper), maximal current density (j lower), statistical analysis of AP numbers (**k**) and Na~V~1.8 currents (**l**) of DRG 1 month post sham or ACLT. \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 compared with the sham-operated group at different time points. Statistical significance was determined by multifactorial ANOVA WITH BONFERRONI POST HOC TEST (**c, k, l**), unpaired Student's *t* test (e an i) and all data are shown as scattered plots with means ± standard deviations.\
Figure 1---source data 1.Raw data of Navs QPCR, subchondral Nav1.8 fiber density, Retrograde tracing, Von Frey tests, GcAMP3 imaging, and electrophysiological recordings.\
Figure 1---source data 2.Full scan of western blots in [Figure 1f](#fig1){ref-type="fig"}.](elife-57656-fig1){#fig1}

Excessive PGE2 secreted by osteoblasts modifies Na~V~1.8 for OA {#s2-2}
---------------------------------------------------------------

We then examined the mechanism of upregulation of Na~V~1.8 expression during OA progression. To examine whether excessive PGE2 contributes to the upregulation of Na~V~1.8, we firstly performed immunostaining of cyclooxygenase 2 (Cox2) in subchondral bone sections. Cox2 expression was significantly increased in subchondral bone and primarily in osteocalcin positive osteoblastic cells post ACLT mice compared with sham-operated mice ([Figure 2a and b](#fig2){ref-type="fig"}). Consistently, PGE2 concentration in subchondral bone increased about three times in OA mice relative to sham-operated mice ([Figure 2c](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1a--d](#fig2s1){ref-type="fig"}). To examine if elevated PGE2 upregulates the expression of Na~V~1.8 for the mechanical allodynia in OA, we generated osteoblast specific *Cox2* deficient mice (*Cox2~Oc~^-/-^* mice) by crossbreeding *Cox2^fl/fl^* mice with *Bglap-Cre* mice. PGE2 concentration in subchondral bone was significantly lower in *Bglap-Cre::Cox2^fl/fl^* mice compared with *Cox2^fl/fl^* mice post ACLT ([Figure 2h](#fig2){ref-type="fig"}). Notably, the Na~V~1.8 immunofluorescence intensity in subchondral bone immunostaining was also significantly reduced in *Bglap-Cre::Cox2^fl/fl^* mice compared with *Cox2^fl/fl^* mice ([Figure 2d and i](#fig2){ref-type="fig"}). In addition, the number of Na~V~1.8^+^ neurons in DRG was also significantly decreased ([Figure 2e and j](#fig2){ref-type="fig"}) in the *Bglap-Cre::Cox2^fl/fl^* mice relative to *Cox2^fl/fl^* mice. We then investigated whether a decrease of PGE2 alleviates OA pain. We crossed *Bglap-Cre::Cox2^fl/fl^* mice with *Pirt ^GCaMP3fl/-^* mice to measure the DRG neuronal excitability in *Bglap-Cre::Cox2^fl/fl^::Pirt ^GCaMP3fl/-^* mice post ACLT. Pirt-GCaMP3 DRG imaging showed that the number of excited neurons was significantly reduced in *Bglap-Cre::Cox2^fl/fl^::Pirt^GCaMP3fl/-^* mice compared with *Cox2^fl/fl^::Pirt ^GCaMP3fl/-^* mice post ACLT ([Figure 2f and k](#fig2){ref-type="fig"}). Moreover, the single neuron excitability in ipsilateral L4 DRG was functionally tested by whole cell patch clamp electrophysiology. The whole cell current clamp revealed that the action potential firing number was significantly decreased in *Bglap-Cre::Cox2^fl/fl^* mice compared with *Cox2^fl/fl^* mice after ACLT ([Figure 2g and l](#fig2){ref-type="fig"}). Concurrently, the Na~V~1.8 current density was reduced for about 40% recorded by the whole-cell voltage-clamp ([Figure 2g and m](#fig2){ref-type="fig"}). The mechanical allodynia was simultaneously attenuated in *Bglap-Cre::Cox2^fl/fl^*mice relative to *Cox2^fl/fl^* mice as revealed by the Von Frey behavior test ([Figure 2n](#fig2){ref-type="fig"}). Catwalk analysis also showed that the Maximal Contact At and Maximal Intensity of ipsilateral hind paw was significantly higher in *Bglap-Cre::Cox2^fl/fl^* mice compared with *Cox2^fl/fl^* mice post ACLT ([Figure 2o](#fig2){ref-type="fig"}). Thus, PGE2 derived from osteoblastic cells stimulates the pain hypersensitivity in OA mice likely by upregulating of Na~V~1.8 in subchondral nociceptive neurons.

![Decreased Na~V~1.8 expression and ameliorated OA progression in Cox2:OCN cKO ACLT mice.\
(**a,b**) Representative pictures (**a**) and statistical analysis (**b**) of OCN and Cox2 co-stained cells of murine tibial subchondral bone after sham or ACLT surgery and 1 m. Scale bars, 50 μm (left) and 10 μm (right), n = 6 per group. (**c**) Relative concentration of subchondral PGE2 compared with total protein concentration before and after ACLT. (**e--g**) Nav1.8 (green) immunostaining in subchondral bone (**d**), NeuN (red), Na~V~1.8 (green) and DAPI (blue) co-immunostaining in ipsilateral L4 DRG (**e**), Activated neurons in ipsilateral L4 DRG using in vivo Pirt-GCaMP3 imaging (**f**) and AP traces and Na~V~ currents (**g**) after sham or ACLT surgery at 1 m. Scale bars, 20 μm (**h**), 100 μm (**e, f**). (**h--o**) Statistical analysis of subchondral PGE2 concentration (**h**), Na~V~1.8 immunofluorescence signal in subchondral bone (**i**), number of NeuN, Nav1.8 co-immunostained neurons in ipsilateral L4 DRG (**j**), number of activated neurons in ipsilateral L4 DRG using in vivo Pirt-GCaMP3 imaging (**k**), AP traces (**l**) and Na~V~ currents (**m**), Catwalk gait analysis (**n**) and left HPWT (**o**) after sham or ACLT surgery. n = 6 per group, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 compared with the sham-operated group at different time points. Statistical significance was determined by multifactorial ANOVA WITH BONFERRONI POST HOC TEST (**h**) or unpaired Student's *t* test (**b, c, h--m and o**), and all data are shown as scattered plots with means ± standard deviations.\
Figure 2---source data 1.Raw data of OCN Cox2 costaining, subchondral PGE2, *GcAMP3* imaging, NeuN Nav1.8 merged neurons, electrophysiological recordings, Von Frey tests and catwalk analysis.](elife-57656-fig2){#fig2}

PGE2 signals through the EP4 receptor to sensitize sensory nerves in OA subchondral bone {#s2-3}
----------------------------------------------------------------------------------------

To examine whether EP4 at sensory neurons is the primary receptor that propagates PGE2 signals in upregulating Na~V~1.8and OA pain, we specifically knocked out EP4, the skeletal pain related receptor for PGE2 ([@bib72]), in peripheral sensory nerves by crossbreeding *Advillin-Cre (Avil-Cre*) ([@bib75]) mice with *Ptger4 ^fl/fl^* mice (*Ptger4* is the gene that encodes EP4 receptor). Consistently with *Bglap-Cre::Cox2^fl/fl^* mice, the intensity of Na~V~1.8 immunofluorescence was significantly reduced in *Avil-Cre::Ptger4 ^fl/fl^* mice compared with *Ptger4 ^fl/fl^* mice post-ACLT ([Figure 3a,d](#fig3){ref-type="fig"}, [Figure 2---figure supplement 1e--h](#fig2s1){ref-type="fig"}). We then further confirm this finding in DRG neurons that cultured in PGE2. We found that Na~V~1.8 protein expression was significantly reduced by siRNA against EP4 in western blot analysis of levels from the cell lysates. Knocking-down the expression of EP1-EP3 did not have a significant effect on Nav1.8 expression ([Figure 2---figure supplement 1i](#fig2s1){ref-type="fig"}). To determine the effect of conditional deletion of EP4 on DRG neuronal excitability, we generated *Avil-Cre::Ptger4 ^fl/fl^::Pirt - GCaMP3^fl/-^* and *Ptger4 ^fl/fl^::Pirt ^GCaMP3fl/-^* ACLT mice. In vivo ipsilateral L4 DRG *Pirt ^GCaMP3^* imaging demonstrated significantly dampened excitability in the *Ptger4 ^fl/fl^:: Pirt - GCaMP3^fl/-^* mice relative to the control group ([Figure 3b and e](#fig3){ref-type="fig"}). The patch-clamp analysis further revealed that the DRG neuronal hypersensitivity and Na~V~1.8 currents were significantly reduced in *Avil-Cre::Ptger4 ^fl/fl^* mice relative to *Ptger4 ^fl/fl^* mice post-ACLT ([Figure 3c,f,g](#fig3){ref-type="fig"}). Moreover, both Von Frey test and catwalk analysis showed attenuation of OA pain when EP4 is conditionally deleted in sensory neurons ([Figure 3h and i](#fig3){ref-type="fig"}). Thus, the EP4 receptor expressed in DRG neurons is responsible for the propagation of subchondral PGE2-induced upregulation of Na~V~1.8 and neuronal excitability in OA mice.

![Decreased Na~V~1.8 expression and ameliorated mechanical allodynia in *Avil-Cre*::*Ptger4^fl/fl^* ACLT mice.\
(**a, b**) Na~V~1.8 immunostaining in subchondral bone (**a**), Activated neurons in ipsilateral L4 DRG using in vivo Pirt-GCaMP3 imaging (**b**) after sham or ACLT surgery at 1 m. Scale bars, 20 μm (**a**), 100 μm (**b**). (**c**) Representative traces of action potentials (upper) and Nav1.8 currents (lower) of ipsilateral L3-5 DRG neurons after sham or ACLT surgery at 1 m. (**d--i**) Statistical analysis of Nav1.8 immunofluorescence signal in subchondral bone (**d**), number of activated neurons in ipsilateral L4 DRG using in vivo Pirt-GCaMP3 imaging (**e**), AP traces (**f**), max Nav1.8 current density (**g**), catwalk gait analysis (**h**) and left hindpaw PWT (**i**) after sham or ACLT surgery. n = 6 per group, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 compared with the sham-operated group at different time points. Statistical significance was determined by multifactorial ANOVA WITH BONFERRONI POST HOC TEST (**i**) or unpaired Student's *t* test (**d--h**), and all data are shown as scattered plots with means ± standard deviations.\
Figure 3---source data 1.Raw data of subchondral Nav1.8 fiber density, Von Frey tests, catwalk analysis, *GcAMP3* imaging, and electrophysiological recordings.](elife-57656-fig3){#fig3}

PGE2 stimulates Na~V~1.8 transcription by inducing the binding of pCREB to Na~V~1.8 promoter {#s2-4}
--------------------------------------------------------------------------------------------

To investigate the mechanism of PGE2 stimulated upregulation of Na~V~1.8 expression, RT-qPCR was performed with mRNA isolated from primary DRG neurons treated with PGE2. The result showed that Na~V~1.8 transcription levels were significantly elevated at 6 and 12 hr after incubation with PGE2 ([Figure 4a](#fig4){ref-type="fig"}). Moreover, PGE2 stimulated phosphorylation of protein kinase A (PKA) ([@bib26]) and cAMP response element-binding protein (Creb1) ([@bib45]; [Figure 4b](#fig4){ref-type="fig"}). Notably, the effect of PGE2 and Forskolin, a cAMP stimulant in the upregulation of Na~V~1.8 protein expression was dampened by Creb1 inhibitor 666--15 ([Figure 4c](#fig4){ref-type="fig"}), indicating PGE2 stimulates Nav1.8 expression through the PKA-Creb1 signaling pathway. Consistently, the neuronal excitability and Na~V~1.8 current density stimulated by PGE2 was abolished by the application of PKA inhibitor (PKI) or CREB inhibitor 666--15 ([Figure 4d--f](#fig4){ref-type="fig"}). Co-immunofluorescence staining further demonstrated that PKA levels significantly increased in Na~V~1.8 positive DRG neurons in ACLT mice compared with sham-operated mice ([Figure 4g and h](#fig4){ref-type="fig"}). To examine the mechanism of PGE2-induced Na~V~1.8 transcription, we performed chromatin immunoprecipitation (ChIP) assay with three potential pCreb1-binding elements in the Na~V~1.8 promoter. ChIP assay revealed that pCreb1 binds to the Na~V~1.8 promoter at binding site two to stimulate transcription of Na~V~1.8 gene ([Figure 4i--k](#fig4){ref-type="fig"}). Taken together, our findings reveal that PGE2 induces transcription of Na~V~1.8 by stimulation phosphorylation PKA and pCreb1, which directly binds to Na~V~1.8 promoter.

![PGE2 upregulates Na~V~1.8 through PKA signaling.\
(**a**) RT-QPCR analysis of Nav1.8 in cultured lumbar DRG neurons treated with PGE2 (1 μM) for 2--12 hr. n = 6 per group. (**b**) Representative of western blots of PKA-c, CREB and p-CREB in cultured lumbar DRG neurons treated with PGE2 (1 μM) for 40--160 min. (**c**) Representative of western blots of the Nav1.8 in cultured lumbar DRG neurons treated with PGE2 (1 μM), forskolin (10 μM), or 666--15 (1 μM) for 6 hr. Representative traces of action potentials (d, upper) and Nav1.8 currents (d, lower) and statistical analysis of maximal Nav1.8 current density (**f**) of cultured lumbar DRG neurons after sham or ACLT surgery at 1 m. n = 6 per group. (**e, f**) Co-immunostaining of NeuN and Nav1.8 (**g**) and statistical analysis of merged cell numbers (**h**) in ipsilateral L4 DRGs after sham or ACLT surgery at 1 m. n = 6 per group.(**i--k**) ChIP experiment showing putative primers (**i**), PCR (**j**) and gel running results (**k**) of Na~V~1.8 promoter, the experiments were repeated three times. n.s, non significant, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 compared with the sham-operated group at different time points. Statistical significance was determined by multifactorial ANOVA WITH BONFERRONI POST HOC TEST (**a, e and f**), unpaired Student's *t* test (**h**), all data are shown as scattered plots with means ± standard deviations.\
Figure 4---source data 1.Raw data of Navs QPCR, subchondral Nav1.8 fiber density, Retrograde tracing, Von Frey tests, GcAMP3 imaging, and electrophysiological recordings.\
Figure 4---source data 2.Full scan of western blots in [Figure 4b](#fig4){ref-type="fig"}.\
Figure 4---source data 3.Full scan of western blots in [Figure 4c](#fig4){ref-type="fig"}.\
Figure 4---source data 4.Full scan of western blots in [Figure 4k](#fig4){ref-type="fig"}.](elife-57656-fig4){#fig4}

The deletion of Na~V~1.8 in sensory nerve attenuates OA {#s2-5}
-------------------------------------------------------

We next tested whether the deletion of Na~V~1.8^+^ neurons could attenuate OA pain. *Scn10a* **-Cre** mice were crossed with *Rosa26^iDTRfl/fl^* mice to generate *Scn10a -Cre:: Rosa26^iDTRfl/fl^* mice. In these mice, the Na~V~1.8^+^ neurons underwent apoptosis upon receiving the injection of diphtheria toxin ([@bib12]). The ablation of Na~V~1.8^+^ neurons had no effect on the articular cartilage deterioration, as shown by similar OARSI scores between *Scn10a -Cre:: Rosa26^iDTRfl/fl^* mice and *Rosa26^iDTRfl/fl^* mice post-ACLT ([Figure 5a,e](#fig5){ref-type="fig"}). The efficacy of specific neuron ablation was evidenced by a significant reduction of Na~V~1.8^+^ signals at both subchondral bone and DRG level ([Figure 5b,c,f,g](#fig5){ref-type="fig"}). Consistently, the DRG hypersensitivity was reduced as indicated by a decreased AP firing ([Figure 5d and h](#fig5){ref-type="fig"}). We further investigated whether the ablation of Na~V~1.8^+^ sensory neurons reduces the pain in OA mice by catwalk gait analysis ([@bib39]). The results showed that max intensity, which reflected mechanical pain sensitivity ([@bib31]), was increased in *Scn10a -Cre:: Rosa26****^iDTRfl/fl^*** mice ([Figure 5i](#fig5){ref-type="fig"}). Similarly, the Von Frey test displayed a significant reduction of HPWT in *Scn10a -Cre:: Rosa26^iDTRfl/fl^* mice compared with *Rosa26^iDTRfl/fl^* mice after ACLT ([Figure 5j](#fig5){ref-type="fig"}). Taken together, the *Scn10a -Cre:: Rosa26****^iDTRfl/fl^*** mice indicates that specific ablation Na~V~1.8 can alleviate OA pain in OA mice.

![Mechanical allodynia is reduced in *Scn10a-Cre*::*Rosa26^iDTRfl/fl^* ACLT mice.\
(**a--d**) Representative photos of knee joint Safranin Orange and fast green staining (**a**), Na~v~1.8 (green) and DAPI (blue) immunofluorescence in subchondral bone (**b**) and NeuN (red, Na~v~1.8 (green) and DAPI (blue) co-immunostaining of ipsilateral L4 DRGs (**c**) and APs (**d**) after sham or ACLT surgery at 1 m. Scale bars, 500 μm (**a**), 20 μm (**b**) and 100 μm (**c**), n = 6 per group. (**e--j**) Statistical analysis of OARSI score (**e**), Nav1.8 immunofluorescence signal in subchondral bone (**f**), number of NeuN, Na~v~1.8 co-immunostained neurons in ipsilateral L4 DRG (**g**), number of AP (**h**), catwalk gait analysis (**i**) and left hindpaw PWT (**j**) after sham or ACLT surgery. n = 6 per group, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 compared with the sham-operated group at different time points. Statistical significance was determined by multifactorial ANOVA WITH BONFERRONI POST HOC TEST (**e--h and j**) or unpaired Student's *t* test (**i**), and all data are shown as scattered plots with means ± standard deviations.\
Figure 5---source data 1.Raw data of OARSI, subchondral Nav1.8 fiber density, NeuN nav1.8 costaining, Von Frey tests, catwalk analysis, GcAMP3 imaging, and electrophysiological recordings.](elife-57656-fig5){#fig5}

Improvement of subchondral bone structure downregulates Na~V~1.8 and attenuates OA progression {#s2-6}
----------------------------------------------------------------------------------------------

We previously showed that inhibition of excessive TGF-**β** activity attenuated OA progression by restringing the coupling of subchondral bone remodeling ([Figure 6---figure supplement 1a--n](#fig6s1){ref-type="fig"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} 4a-e). We have developed a small molecule drug by conjugating TGF-**β** type I receptor kinase inhibitor (TβR1I) covalently with alendronate through a metabolically cleavable carbamate linkage ([@bib58]). The conjugate is effectively delivered to the bone surface where TβR1I is released by cleavage of the carbamate linkage in vivo. ([Figure 6---figure supplement 3a](#fig6s3){ref-type="fig"}). Administration of the conjugate in human MSCs effectively inhibited TGF-β signaling evidenced by a significant reduction of pSMAD2/3 ([Figure 6---figure supplement 3b and c](#fig6s3){ref-type="fig"}). As excessive PGE2 production and subsequent upregulation of Nav1.8 are triggered by abnormal bone remodeling, we investigated whether conjugate treatment can alleviate OA pain by downregulates the activity of Nav1.8. As expected, the articular cartilage degeneration was attenuated with a weekly injection of conjugate 100 ug/kg in ACLT mice compared with the vehicle group, with a significant improvement of the OARSI score ([Figure 6a and g](#fig6){ref-type="fig"}). In concurrent with the cartilage protection, the subchondral bone microarchitecture was improved in μCT analysis of ACLT mice treated with the conjugate treatment compared with the vehicle group ([Figure 6b and h](#fig6){ref-type="fig"}, [Figure 6---figure supplement 3f](#fig6s3){ref-type="fig"}). As shown in [Figure 6c and i](#fig6){ref-type="fig"}, phosphorylation of Smad2/3 was effectively inhibited by the conjugate in the subchondral bone. The number of TRAP^+^ osteoclastic cells and Osterix^+^ pre-osteoblast were reduced ([Figure 6---figure supplement 3e and g](#fig6s3){ref-type="fig"}, [Figure 6d and j](#fig6){ref-type="fig"}). As a result, the BML in tibial subchondral bone was significantly reduced in the conjugate treated group ([Figure 6f](#fig6){ref-type="fig"}) further indicating that coupling of the osteoclast bone resorption and osteoblastic bone formation were restored.

![Targeting aberrant subchondral bone remodeling reduces Na~V~1.8^+^ innervation and ameliorates OA pain.\
(**a--f**) Representative photos of Safranin Orange and fast green staining (**a**), μCT 3D reconstruction (**b**), pSMAD2/3 (red) and DAPI (blue) immunostaining (**c**) Osterix immunostaining (**d**) Nav1.8 (green) and DAPI (blue) immunostaining (**e**) and T2 weighted fat suppression μMRI image showing bone marrow lesion (yellow arrows) (**f**) of murine tibial subchondral bone after sham or ACLT surgery at 1 m. Scale bars, 500 μm (**a**), 2 mm (**b**), 10 μm (**c, d**), 20 μm (**e**), and 5 mm (**f**), n = 6 per group. (**g--l**) Quantitative analysis of OARSI score (**g**), BV/TV (**h**), number of pSMAD2/3^+^ cells per mm^2^ (**i**) and number of Osterix^+^ cells per mm^2^ (**j**), relative pixel of Nav1.8 immunofluorescence signal (**k**) and subchondral PGE2 concentrations (**l**), after sham or ACLT surgery at 1 m. (**m**) Representative western blots of Na~V~1.8 and GAPDH of ipsilateral L3-5 DRG lysate, experiments were repeated three times. (**n--p**) Representative traces of Aps (n upper), maximal current density (n lower), statistical analysis of AP numbers (**o**) and Na~V~1.8 currents (**p**) of DRG 1 month post sham or ACLT. (**q, r**), left HPWT (**q**) and catwalk gait analysis (**r**) n = 6 per group, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 compared with the sham-operated group at different time points. Statistical significance was determined by multifactorial ANOVA WITH BONFERRONI POST HOC TEST (**j, k, L, m, n, o, q and r**) or unpaired Student's *t* test (**c**), and all data are shown as scattered plots with means ± standard deviations.\
Figure 6---source data 1.Raw data of OARSI, microCT data, Osx, TRAP, pSMAD2/3, subchondral Nav1.8 fiber density, Retrograde tracing, Von Frey tests, GcAMP3 imaging, and electrophysiological recordings.\
Figure 6---source data 2.Full scan of western blots in [Figure 6m](#fig6){ref-type="fig"}.](elife-57656-fig6){#fig6}

Finally, we examined whether the conjugate effect on the improvement of subchondral bone structure and articular cartilage degeneration could also relieve OA pain. Interestingly, subchondral PGE2 concentration was significantly reduced in ACLT mice with the conjugate treatment relative to the vehicle group ([Figure 6l](#fig6){ref-type="fig"}). Importantly, the expression of Na~V~1.8 was also reduced in both subchondral bone ([Figure 6e and k](#fig6){ref-type="fig"}), and ipsilateral lumbar DRG ([Figure 6m](#fig6){ref-type="fig"}). Moreover, the electrophysiological tests demonstrate that data showed that conjugate treatment blunted the upregulation of DRG neuron activity ([Figure 6n and o](#fig6){ref-type="fig"}) and Na~V~1.8 currents ([Figure 6n and p](#fig6){ref-type="fig"}) in ACLT mice. The effect of the conjugate on joint pain related behaviors were examined in the Catwalk test. HPWT, maximal contact AT and swing phase were significantly ameliorated in ACLT mice with the administration of conjugate relative to the vehicle group ([Figure 6q and r](#fig6){ref-type="fig"}). These data suggest that alendronate-TβR1I conjugate relieves OA pain by modifying the disease. This was likely achieved by the decrease of PGE2 in the improvement of subchondral bone structure.

Discussion {#s3}
==========

Pain is the major symptom of OA, the most prevalent skeletal degenerative disease with no effective disease-modifying drugs. To date, the major local source and pathophysiological mechanisms of OA pain remain poorly understood, impeding the development of mechanism based strategies for OA pain attenuation. Based on clinical observations, in this study, we hypothesized that aberrant subchondral bone remodeling could be highly responsible for OA pain. Aberrant bone remodeling significantly stimulates the PGE2 production in subchondral bone, with the osteoblastic cell being the major source of production. Accordingly, OA pain alleviation can be achieved by specifically knocking out the PGE2 producing enzyme Cox2 in osteoblast or its receptor EP4 in peripheral sensory nerve, likely through reducing the expression of Na~V~1.8. In particular, the direct ablation of Na~V~1.8^+^ DRG neurons demonstrates that Na~V~1.8 overexpression at least partially mediates neuronal hypersensitivity in OA progression. Importantly, we demonstrated that pharmacologically inhibition of aberrant bone remodeling has superior treatment effect than purely blocking pain transduction pathway as evidenced by that conjugate improved subchondral bone structure, attenuated cartilage degeneration and ameliorated OA pain simultaneously while deleting Na~V~1.8^+^ neurons only alleviated OA pain without disease-modifying effect in OA pathologies.

Generally, central ([@bib37]) and peripheral sensitization ([@bib54]) are two principal components for OA pain. Since surgical removal of a part of arthritic knee joint in total knee replacement can immediately relieve OA pain ([@bib61]), it is believed that peripheral input is indispensable in OA pain sensitization. Several joint structures are plausible sources of OA pain (e.g., the synovium, tendons), but clinical tests do not reliably attribute the pain to those structures. Synovium, because of its dense innervation of sensory nerves, is thought to be one of the important sources of OA pain ([@bib33]). Low grade of synovitis in OA could also be able to stimulate sensory nerve endings. However, human studies showed that synovial sensory nerve declined in some of the degenerative OA patients ([@bib17]; [@bib60]), making this hypothesis inconclusive. Similarly, the increase of vascular and nerve growth in meniscus ([@bib4]) and fat pad ([@bib9]) suggests that they might also be a source of pain. Several lines of clinical evidence point to the potential role of subchondral bone in the mechanical allodynia during OA progression ([@bib38]; [@bib74]). This is clinically supported by the immediate pain relief in OA patient after removal of degraded cartilage and underlying subchondral bone in joint surgery ([@bib56]). Since articular cartilage is not innervated by sensory nerve, therefore, the densely innervated subchondral bone could be an essential local source for clinical OA pain. Identifying the main source of pain and related mechanisms is essential for the treatment of OA pain. The subchondral bone transmits mechanical loads produced by body weight and muscle activity. It is highly adaptable, with the ability to model and remodel in response to loading stresses. During OA development, the subchondral bone undergoes aberrant remodeling, leading to pathologic lesions. MRI studies have shown lower bone mineral density, also known as bone marrow lesions (BML), and more severe disruption of subchondral bone architecture in patients with OA ([@bib18]; [@bib46]). Subchondral BML is the first sign of OA in animal models ([@bib42]) and strongly correlate with knee pain in humans ([@bib16]). We previously have demonstrated aberrant bone remodeling of subchondral bone at the onset and pathological development of OA ([@bib73]). Studies have showed perivascular sensory and sympathetic nerve fibers breach the subchondral bone in OA compared to normal joint ([@bib49]; [@bib69]). Recently, we found that excessive Netrin-1 secreted by osteoclasts in subchondral bone induces sensory nerve axonal growth in OA ([@bib74]). We also found that during bone remodeling, PGE2, produced from arachidonic acid by the enzymatic activity of Cox2, activates EP4 in sensory nerves. In the present study, we found that the abnormal bone remodeling and temporary decrease of bone density in subchondral bone at the early stage of OA resembles the pathological changes as seen in osteoporosis. This explains why Cox2 activity and subsequent PGE2 production increased in response to the structural changes in OA subchondral bone. The increased nociceptive innervation to OA subchondral bone secondary to excessive netrin-1 secretion by the osteoclasts therefore favors the PGE2 induced neuronal excitations. Taken together, we believe that the development of OA pain is a synergistic result involving central sensitization in spinal cord in conjunction with peripheral input from subchondral bone, synovium, meniscus and fat pad etc.

The molecular mechanism of neuronal sensitization remains a poorly understood facet of OA pathophysiology. It is widely accepted that neuronal plasticity including activation, transcriptional modification and post-transcriptional of ion channels related to electrical excitability could contribute to the generation of chronic pain ([@bib70]). Giving the essential role of action potential firing in peripheral nerve input, the possible involvement of ion channels was investigated in recent studies. Our findings suggest that Na~V~1.8 is the most upregulated Na~V~ channel with a restricted localization in DRG. We therefore focused on Na~V~1.8 to the possible molecular events based on the extensive over-activation of subchondral bone remodeling in OA progression. We found the expression rate of Na~V~1.8 was significantly elevated in subchondral bone marrow, sciatic nerve and ipsilateral lumbar DRG levels. And the further screening analysis showed the expression rate of Na~V~1.8 mainly elevated in CGRP^+^ nociceptive fiber and piezo2^+^ low threshold mechanoceptive fibers. This pattern of modification of Na~V~1.8 expression in sensory neurons could explain the high sensitivity in polymodal nociception and mechanoception after ACLT. Functionally, this upregulation of expression led to larger Na~V~1.8 currents and higher excitability of DRG neurons after ACLT. The Na~V~1.8 currents are thought to be essential for action potential firing at the initial state. Being activated by PGE2, the lager Na~V~1.8 currents could make the DRGs easier for action potential firing, thus transmitting the pain signals into higher centers for mechanical allodynia. In the short term, phosphorylation of Na~V~1.8 by PGE2 may increase the inward currents by opening the Na~V~1.8 ion gating mechanism ([@bib28]). Also, PGE2 increases the expression of Na~V~1.8 in a relatively long term of stimulation by PKA signaling. However, the role of other modalities of modulations like phosphorylation, methylglyoxalation need to be investigated in future studies. Nevertheless, future studies should be conducted to explain how this elevation of Na~V~1.8 could be integrated and translated into the central nervous system as pain signals.

Pain sensation and OA progression are often dissociated. Late stage of radiographic OA patients with extensive subchondral bone sclerosis may result in less pain sensation and early stage patients with significant subchondral BML can be very painful. Moreover, the anti-nerve growth factor (NGF) tanezumab administration to OA patients relief pain with no significant attenuation on OA cartilage protection or subchondral bone sclerosis ([@bib41]). Consistently, although pain relief can be achieved to some extent by targeting Na~V~1.8, the cartilage or subchondral bone was not significantly protected in OA progression after ACLT in our study. These results indicate a comprehensive therapy for OA should target upstream events that cause OA progression and pain. Here, we provide a proof of principle for the potential of small molecule drug balancing aberrant bone remodeling to attenuate mechanical allodynia and OA progression in general. We achieved the bone-targeted TGF-β inhibition by conjugating the TGF-β type I receptor inhibitor (LY-2109761 with an osteoclast targeting drug alendronate. Consistent with our previous findings, the conjugate rebalanced the uncoupled subchondral bone remodeling and reduced over-activated osteoblastic bone formation through targeting aberrant TGF-β signaling in ACLT mice model. This rebalance was effective in pain alleviation through a reduction of excessive PGE2 released into subchondral bone marrow and down-regulation of Na~V~1.8 expression and electric property to reduce mechanical allodynia in OA. Meanwhile, the reconstruction of subchondral bone architecture protected the overlying cartilage destruction and delayed the progression of the overall OA process ([Figure 7](#fig7){ref-type="fig"}). We believe this mechanism based management of OA pain may shed light on the strategy of various musculoskeletal disorders with chronic pain symptom. Nevertheless, because the pharmacological or toxicological aspect of the conjugate in vivo are largely unknown, further enhancement of therapeutic effect may be achieved with optimization of dosing and delivery strategies.

![The working model of osteoblastic PGE2 induces OA progression by Na~V~1.8 modification.](elife-57656-fig7){#fig7}

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                           Source or reference   Identifiers                                                                                                        Additional information
  (species) or resource                                                                                                                                                                                                       
  -------------------------------------------- ------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------------------ -----------------------------------------
  Strain, Strain backgroud\                    *Ptger4^floxed^*                      ([@bib15])            N/A                                                                                                                C57BL/6 background
  (*Mus musculus*)                                                                                                                                                                                                            

  Strain, Strain background\                   *Bglap-Cre*                           ([@bib66])            N/A                                                                                                                C57BL/6 background
  (*Mus musculus*)                                                                                                                                                                                                            

  Strain, Strain background\                   **Pirt-^GcaMP3\ floxed^**             ([@bib34])            N/A                                                                                                                C57BL/6 background
  (*Mus musculus*)                                                                                                                                                                                                            

  Strain, Strain background\                   *Advillin-Cre(Avil-Cre)*              ([@bib75])            N/A                                                                                                                C57BL/6 background
  (*Mus musculus*)                                                                                                                                                                                                            

  Strain, Strain background\                   *Rosa26^iDTRfloxed^*                  Jackson Laboratory    C57BL/6-Gt(ROSA)26Sortm1(HBEGF)Awai/J Stock No: 007900                                                             C57BL/6 background
  (*Mus musculus*)                                                                                                                                                                                                            

  Strain, Stran background Rattus norvegicus   Sprague Dawley (SD)                   Charles River         N/A                                                                                                                

  Strain, Strain backgroud\                    *Scn10a-Cre*                          ([@bib19])            N/A                                                                                                                C57BL/6 background
  (*Mus musculus*)                                                                                                                                                                                                            

  Strain, Strain backgroud\                    *Cox2 ^floxed^*                       Harvey Herschman      N/A                                                                                                                C57BL/6 background
  (*Mus musculus*)                                                                                                                                                                                                            

  Sequence- based reagent                      *Scn10a-Cre* forward                                        PCR Primer                                                                                                         5′-TGTAGATGGACTGCAGAGGATGGA-3′

  Sequence- based reagent                      *Scn10a-Cre* reverse                                        PCR Primer                                                                                                         5′-AAATGTTGCTGGATAGTTTTTACTGCC-3′

  Sequence- based reagent                      **Pirt-^GCaMP3\ fl^ primer 1**                              PCR Primer                                                                                                         5′-TCCCCTCTACTGAGAGCCAG-3′

  Sequence- based reagent                      **Pirt-^GCaMP3fl^** primer 2                                PCR Primer                                                                                                         5′-GGCCCTATCATCCTGAGCAC-3′

  Sequence- based reagent                      **Pirt-^GCaMP3fl^** primer 3                                PCR Primer                                                                                                         5′-ATAGCTCTGACTGCGTGACC-3′

  Sequence- based reagent                      **Avil-Cre**: forward                                       PCR Primer                                                                                                         5′-CCCTGTTCACTGTGAGTAGG-3′

  Sequence- based reagent                      **Avil-Cre**: reverse                                       PCR Primer                                                                                                         5′-GCGATCCCTGAACATGTCCATC-3′

  Sequence- based reagent                      **Avil-Cre**: wildtype                                      PCR Primer                                                                                                         5′-AGTATCTGGTAGGTGCTTCCAG-3′

  Sequence- based reagent                      **Bglap-Cre:** forward                                      PCR Primer                                                                                                         5′-CAAATAGCCCTGGCAGATTC-3′

  Sequence- based reagent                      **Bglap-Cre**: reverse                                      PCR Primer                                                                                                         Reverse: 5′-TGATACAAGGGACATCTTCC-3′

  Sequence- based reagent                      **Cox2** loxP allele forward:                               PCR Primer                                                                                                         5**′**-AATTACTGCTGAAGCCCACC-3

  Sequence- based reagent                      **Cox2** loxP allele reverse                                PCR Primer                                                                                                         5**′**-GAATCTCCTAGAACTGACTGG-3**′**

  Sequence- based reagent                      *Ptger4* loxP allele forward                                PCR Primer                                                                                                         5**′**-TCTGTGAAGCGAGTCCTTAGGCT-3**′**

  Sequence- based reagent                      *Ptger4* loxP allele reverse                                PCR Primer                                                                                                         5**′**-CGCACTCTCTCTCTCCCAAGGAA-3**′**

  Sequence- based reagent                      *Rosa26^iDTRfloxed^* forward                                PCR Primer                                                                                                         5**′**-GCGAAGAGTTTGTCCTCAACC-3**′**

  Sequence- based reagent                      *Rosa26^iDTRfloxed^* reverse                                PCR Primer                                                                                                         5**′**-AAAGTCGCTCTGAGTTGTTAT-3**′**

  Sequence- based reagent                      **Gapdh** forward                                           RT-PCR Primer                                                                                                      5′-TCCATGACAACTTTGGCATTG-3′

  Sequence- based reagent                      **Gapdh reverse**                                           RT-PCR Primer                                                                                                      5′-CAGTCTTCTGGGTGGCAGTGA-3′

  Sequence- based reagent                      **Scn1a** forward                                           RT-PCR Primer                                                                                                      5′-AACAAGCTTGATTCACATACAATAAG-3′

  Sequence- based reagent                      **Scn1a** reverse                                           RT-PCR Primer                                                                                                      5′-AGGAGGGCGGACAAGCTG-3′

  Sequence- based reagent                      **Scn2a** forward                                           RT-PCR Primer                                                                                                      5′-GGGAACGCCCATCAAAGAAG-3′

  Sequence- based reagent                      **Scn2a** reverse                                           RT-PCR Primer                                                                                                      5′-ACGCTATCGTAGGAAGGTGG-3′

  Sequence- based reagent                      **Scn3a** forward                                           RT-PCR Primer                                                                                                      5′-AGGCATGAGGGTGGTTGTGAACG-3′

  Sequence- based reagent                      **Scn3a** reverse                                           RT-PCR Primer                                                                                                      5′-CAGAAGATGAGGCACACCAGTAGC-3′

  Sequence- based reagent                      **Scn8a** forward                                           RT-PCR Primer                                                                                                      5′-AGTAACCCTCCAGAATGGTCCAA-3′

  Sequence- based reagent                      **Scn8a** reverse                                           RT-PCR Primer                                                                                                      5′-GTCTAACCAGTTCCACGGGTCT-3′

  Sequence- based reagent                      **Scn9a** forward                                           RT-PCR Primer                                                                                                      5′-TCCTTTATTCATAATCCCAGCCTCAC-3′

  Sequence- based reagent                      **Scn9a** reverse                                           RT-PCR Primer                                                                                                      5′-GATCGGTTCCGTCTCTCTTTGC-3′

  Sequence- based reagent                      **Scn10a** forward                                          RT-PCR Primer                                                                                                      5′-ACCGACAATCAGAGCGAGGAG-3′

  Sequence- based reagent                      **Scn10a** reverse                                          RT-PCR Primer                                                                                                      5′-ACAGACTAGAAATGGACAGAATCACC-3′

  Sequence- based reagent                      **Scn11a** forward                                          RT-PCR Primer                                                                                                      5′-TGAGGCAACACTACTTCACCAATG-3′

  Sequence- based reagent                      **Scn11a** reverse                                          RT-PCR Primer                                                                                                      5′-AGCCAGAAACCAAGGTACTAATGATG-3′

  Sequence- based reagent                      **Creb1**\                                                  ChIP-PCR\                                                                                                          5′-AGTATGGTCCTTCGTGGAATACCAG-3′
                                               forward                                                     Primer 1                                                                                                           

  Sequence- based reagent                      **Creb1**reverse                                            ChIP-PCR\                                                                                                          5′-GCTATACTGCAGGAAACTGGCGA-3′
                                                                                                           Primer 1                                                                                                           

  Sequence- based reagent                      **Creb1**forward                                            ChIP-PCR\                                                                                                          5′-AGCTCCCTTCTCAGCTCTCAC-3′
                                                                                                           Primer 2                                                                                                           

  Sequence- based reagent                      **Creb1**reverse                                            ChIP-PCR\                                                                                                          5′-CAATCTACCCAGTCTCCCTCTTTGG-3′
                                                                                                           Primer 2                                                                                                           

  Sequence- based reagent                      **Creb1**forward                                            ChIP-PCR\                                                                                                          5′-GAGCACCATCCAGCAAGCAG-3′
                                                                                                           Primer 3                                                                                                           

  Sequence- based reagent                      **Creb1**reverse                                            ChIP-PCR\                                                                                                          5′-CCAGCTCTGCGAAACTTACACT-3′
                                                                                                           Primer 3                                                                                                           

  Antibody                                     Rabbit polyclonal Anti-Nav1.8         Alomone Labs          ASC-016,                                                                                                           1:50

  Antibody                                     Rabbit polyclonal Anti-pSmad2/3       Santa Cruz Bio        sc-11769                                                                                                           1:50,

  Antibody                                     Rabbit polyclonal Anti-Osterix        Abcam                 ab22552                                                                                                            1:300

  Antibody                                     Rabbit polyclonal Anti- Osteocalcin   Takara bio Inc,       M173                                                                                                               1:200

  Antibody                                     Rabbit polyclonal Anti- Cox2          Abcam                 ab15191                                                                                                            1:100

  Antibody                                     Mouse monocloncal anti-PKA-c          Abcam                 [ab75991](https://www.abcam.com/pka-alphabetagamma-catalytic-subunit-phospho-t197-antibody-ep2606y-ab75991.html)   1:200

  Software                                     Graphpad 8.0                                                Statistical Analysis                                                                                               graph preparation, statistical analysis
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

We purchased C57BL/6J (WT) 3 months old male mice from Jackson Laboratories. We purchased Sprague Dawley (SD) 3 months old male rats from Charles River company. To develop the mechanical instability related OA model, we used ACLT surgery ([@bib47]). Briefly, after ketamine and xylazine anesthesia, the left ACL was surgically transected and sham operations were performed on other groups of mice. For the time-course experiments, mice were euthanized at 4, 8 or 12 weeks after surgery (n = 6 per group).

The *Rosa26^iDTRfl/fl^* mice were purchased from Jackson Laboratory. The *Advillin-Cre* (*Avil-Cre*) and **Pirt^GCaMP3^** mouse strain were kindly provided by Xingzhong Dong (The Johns Hopkins University). The *Bglap-Cre* mice were provided by Thomas J. Clemens (The Johns Hopkins University). The *Cox2^fl/fl^* mice were kindly provided by Harvey Herschman (University of California, Los Angeles). The *Ptger4 ^fl/fl^* mice were provided by Brian L. Kelsall (the National Institutes of Health). The *Scn10a-Cre* mice were kindly provided by Yun Guan (The Johns Hopkins University). Heterozygous *Bglap-Cre* mice were crossed with a *Cox2^fl/fl^* mouse; the offspring were intercrossed to generate the following genotypes: WT, *Bglap-Cre*, *Cox2^fl/fl^*, *Bglap-Cre::Cox2^fl/fl^. Cox2^fl/fl^* or *Bglap-Cre::Cox2^fl/fl^* **mice were further crossed with *Pirt^GCaMP3fl/-^* mice to generate** *Cox2^fl/fl^***::Pirt^GCaMP3^***^fl/-^* mice or *Bglap-Cre::Cox2***::Pirt^GCaMP3^***^fl/-^* **mice for in vivo *GCaMP3* DRG imaging.** Heterozygous *Avil-Cre* mice were crossed with *Ptger4^fl/fl^* mice. The offspring were intercrossed to generate the following genotypes: wild type (referred as 'WT' in the text), *Avil-Cre* (Cre recombinase expressed driven by Advillin promoter), *Ptger4^fl/fl^*, *Avil-Cre:: Ptger4^fl/fl^* (conditional deletion of EP4 receptor in Advillin lineage cells). *Ptger4^fl/fl^* or *Avil-Cre:: Ptger4^fl/fl^* mice were further crossed with *Pirt-GCaMP3 ^fl/-^* mice to generate *Ptger4^fl/fl^***::Pirt-GCaMP3***^fl/-^* mice or *Avil-Cre:: Ptger4^fl/fl^***::Pirt^GCaMP3^***^fl/^* mice for in vivo *GCaMP3* DRG imaging. Heterozygous *Scn10a-Cre* mice were crossed with the *Rosa26^iDTRfl/f^* mouse; the offspring were intercrossed to generate the following genotypes: WT, *Scn10a-Cre::Rosa26^iDTRfl/fl^*, *Scn10a-Cre::Rosa26^iDTRfl/fl^* mice. We injected 12-week-old *Scn10a-Cre:: Rosa26^iDTRfl/fl^* or *Rosa26^iDTRfl/fl^* mice with 1 μg/kg DTX intraperitoneally three times per week after ACLT for 4 weeks. We obtained femurs, tibiae and DRG from the mice after euthanasia. For conjugate injections, we used intraperitoneal injection method and 1 mg/kg per week dosage according to previous toxicological experiments. All animals were maintained at the animal facility of The Johns Hopkins University School of Medicine. All the experimental protocols were approved by the Animal Care and Use Committee of The Johns Hopkins University (Protocol number: Mo18M308).

Human samples {#s4-2}
-------------

After approval by the Institutional Review Board of The Johns Hopkins Hospital,, we collected tibial plateau specimens from eight individuals with osteoarthritis that underwent total knee arthroplasty. The knee joints from three healthy young adults underwent lower limb amputations after trauma serves as healthy controls. The demographic data of patients were collected. The samples were used to perform histology and immunohistochemistry after decalcification.

Histology {#s4-3}
---------

Immediately after euthanasia, we resected and fixed the animals knee joints or DRG in 10% buffered formalin for 24 hr, decalcified them in 0.5 M ethylenediaminetetraacetic acid (EDTA, pH 7.4) for 14 d and embedded them in paraffin or gelatin solution (20% D-sucrose, 2% [Polyvinylpyrrolidone](https://en.wikipedia.org/wiki/Polyvinylpyrrolidone) (PVP) and 8% gelatin in PBS). Four-micrometer sagittal oriented sections of the medial compartment of left knees were processed for hematoxylin and eosin, safranin orange and fast green and Tartrate-resistant acid phosphatase (TRAP) staining (Sigma). For immunohistology and immunofluorescence, slides (4 μm for immunohistology, 20 μm for DRG, 60 μm for knee immunofluorescence) were incubated with antigen retrieval buffer (Dako, [S169984-2](https://www.chem.agilent.com/store/productDetail.jsp?catalogId=S169984-2)) at 96°C for 15 min, gradually cooled to room temperature and washed with tris-buffered saline with Tween (TBST). After blocking, the slides were incubated with primary antibodies overnight at 4°C. Secondary antibody (1:200) was used to incubate the samples for 1 hr at room temperature. For immunohistochemical staining, a horseradish peroxidase--streptavidin detection system (Dako) was used to detect immunoactivity, followed by counterstaining with hematoxylin (Sigma-Aldrich). For immunofluorescence, the fluorescent conjugated secondary antibody (1:200) was applied. The photographs of the immunohistology sections were recorded by light microscopy (DP71 microscope camera, Olympus) and analyzed by OsteoMeasure XP software (OsteoMetrics). We calculated OARSI scores as previously described ([@bib25]). The OARSI scores were evaluated by two independent graders and the averages were taken. For the immunofluorescence, the photographs were shot under laser confocal microscopy (Zeiss, LSM 780) and Zen 2.2 software.

μCT and in vivo μMRI {#s4-4}
--------------------

The mice knees were scanned using high-resolution μCT (SkyScan 1275, Bruker microCT) as previously described ([@bib73]). The scanner was set at a voltage of 65 kVp, a current of 153 μA and a resolution of 5.7 μm per pixel. We reconstructed and analyzed outcomes using NRecon v1.6, and CTAn v1.9, respectively. Three-dimensional reconstructions were done by CTVol v2.0 (Bruker microCT). We defined the region of interest to cover the trabecular part of the medial compartment of tibial subchondral bone, and five consecutive images from the medial tibial plateau were used for 3-dimensional reconstruction. We analyzed 3D parameters as following: TV (total tissue volume; containing both trabecular and cortical bone), BV/TV (trabecular bone volume per tissue volume) and Tb.Pf (trabecular pattern factor).

We performed in vivo μMRI studies on a horizontal 9.4T Bruker Biospec preclinical scanner according to our previous protocol ([@bib73]). Briefly, we showed subchondral BML by T2-weighted scanning with 2D RARE (rapid acquisition with relaxation enhancement) sequence, a TE/TR (echo time/repetition time) of 15.17 ms/3,000 ms, 30 slices at 0.35 mm thickness, 1.75 cm ×1.75 cm field of view (FOV) with a matrix size of 256 × 128. The fat suppression was done in T2-weighted imaging with a chemical shift selective fat saturation pulse tuned to the fat resonant frequency.

Cell culture {#s4-5}
------------

Bilateral lumbar DRGs were harvested from 4 week male WT mice. For DRG neuron culture medium, MEM was supplemented with 5% fetal bovine serum (Gibco), 2X penicillin and streptomycin solution (Gibco), 1X GlutaMAX (Thermo Fisher), 20 μM 5-fluoro-2-deoxyuridine (Sigma-Aldrich) and 20 μM uridine (Sigma-Aldrich). DRG neurons were digested and dissociated with 1 mg/ml collagenase D (Roche) for 90 min and then 1X TrypLE Express solution (Thermo Fisher) for 15 min. The dissociated DRG neurons were placed on a precoated dish with 100 μg / ml poly-D-lysine (thermal fisher) and 10 μg / ml laminin (thermal fisher). 100 ng / ml Nerve growth factor (R and D) was applied to maintain the neuronal activity. After 24 hr incubation, PGE2 (1 μM) or PBS were applied to stimulate the DRG neurons. In vitro RNA interference was performed using commercially available RNAi products from Thermal Scientific [(s72365](https://www.thermofisher.com/order/genome-database/details/sirna/s72365?CID=&ICID=&subtype=sirna_silencer_select), [s72370](https://www.thermofisher.com/order/genome-database/details/sirna/s72370?CID=&ICID=&subtype=sirna_silencer_select), [s72373](https://www.thermofisher.com/order/genome-database/details/sirna/s72373?CID=&ICID=&subtype=sirna_silencer_select), and [s72375](https://www.thermofisher.com/order/genome-database/details/sirna/s72375?CID=&ICID=&subtype=sirna_silencer_select)) and the protocol was followed by the manufacture's instruction. Briefly, after neuron seeding for 24 hr, media were replaced for the cells to be prepared for transfection. Lipofectamine RNAi MAX (13778100, Invitrogen) was diluted in OptiMEM ([31985062](http://www.thermofisher.com/order/catalog/product/31985062), Thermal Fisher) and incubated for 5 min, then mixed with siRNAs or scramble control RNAs for five mins. Diluted DNA and Lipofectamine RNAi MAX were mixed and incubated at room temperature for 20 min and then used to transfect the DRG neurons. The medium was replaced 10 hr following transfection and neurons were harvested 24 hr after transfection. Similarly, the human GFP labeled MSC was purchased from Cyagen and is cultured in MEM with 10% fetal bovine serum (Gibco), 1X penicillin and streptomycin solution (Gibco).

In vivo Pirt-GCaMP3 DRG imaging {#s4-6}
-------------------------------

We used Pirt-GCaMP3^f/-^ mice in DRG imaging. In order to monitor the activity of large populations of DRG neurons in intact live animals, Dr Xinzhong Dong's Lab developed an in vivo imaging technique by using *Pirt^GCaMP3^* genetically engineered mice, in which the genetic-encoded Ca^2+^indicator *GCaMP3* is specifically expressed in \>95% of all DRG neurons by Pirt promoter ([@bib34]; [@bib36]).After surgical exposure of ipsilateral L4 DRG, in vivo imaging was immediately performed. Similarly as previously described ([@bib55]), the animals were maintained under inhalation anesthesia with assisted ventilation through endotracheal incubation. A laser scanning confocal microscope (Leica LSI microscope system) with a water immersed lens was used to capture the fluorescent signals. Live images were acquired at 10 frames with 600 Hz in frame-scan mode per 6--7 s, at depths below the dura ranging from 0 to 70 µm. 25 g of direct compression was applied to the ipsilateral knee after ACLT or sham surgery using a rodent pincher (IITC Life Science) to stimulate DRG neuronal firing. The duration of the mechanical force application maintained 15--30 s after 40--50 s of baseline imaging and the activated neuron number was counted and analyzed.

Electrophysiology {#s4-7}
-----------------

Whole-cell current-clamp recordings were performed to perform the action potential of DR neurons according to the previous study ([@bib8]). Only small and medium-sized DRG neurons with a resting membrane potential more negative than −40 mV were recorded. The extracellular solution contained (in mM): NaCl 140, KCl 4, CaCl~2~ 2, MgCl~2~ 1; HEPES 10, NaOH 4.55, glucose 5 (pH 7.4, 300--310 mOsm/kg H~2~O). The pipette solution contained (in mM): KCl 135, MgCl~2~ 0.1, Mg-ATP 1.6, HEPES 10, EGTA 2, (pH 7.3 at 25°C, adjusted with NaOH). The voltage was firstly clamped at −60 mV. For action potential stimulation, the frequency is by 2 × and 3 × rheobase and ramp current stimulation (0.1, 0.3, 0.5, and 1.0 nA/sec ramp current).

To measure the TTX resistant Na~V~1.8 currents in DRG neurons, the voltage-clamp technique was used. For recordings on DRG neurons, the extracellular solution contained (mM): NaCl 60, KCl 3, Choline-Cl 80, CaCl~2~ 0.1, MgCl~2~ 0.1, HEPES 10, tetraethylammonium chloride 10, glucose 10 and CdCl~2~ 0.1 (pH adjusted to 7.4, 300--310 mOsm/kg H~2~O) TTX (1 uM) and TC-N 1572 (1.6uM) were applied to the solution to block TTX sensitive sodium current and Na~V~1.9 currents. The pipette solution contained (mM) CsF 140, EGTA 5, MgCl 1, and HEPES 10, glucose 10 (pH 7.4, osmolarity 285--295 mOsm/kg H~2~O). Only cells with an initial seal \>1 GΩ were recorded. The Na~V~1.8 currents were recorded responding to potential from --70 to +50 mV in 10 mV increments. The maximal current densities (pA/pF) were calculated and analyzed.

Behavioral test {#s4-8}
---------------

Electronic Von Frey hair algesiometer (IITC Life Science) was used to measure the hind paw withdrawal threshold. Before starting the test, mice were separately placed in elevated Plexiglas chambers on metal mesh flooring for 30 mins. A von Frey hair with bending force (0.6 g, 1 g, 1.4 g, 2 g, 4 g) was exerted perpendicular to the plantar surface of the hind paw until it just bent and the hind paw of mice of elevated. The force displayed on the electronic device were recorded. The threshold force required to elicit withdrawal of the paw was determined three times on each hind paw and averaged.

Gait analysis was performed on mice 4 weeks after ACLT by the CatWalk system (Noldus) according to our previous protocol ([@bib73]). Briefly, each mouse was placed walkway and allowed to allow the free movement from one side to the other side for at least three times. Mice were trained previously in the formal experiment. After the recording of mouse gait, several parameters were generated, and 5 of the most relevant parameters to OA pain were analyzed. (1) stands, (2) maximal contact at. (3) maximal (4) swing and (5) single stance.

Western blotting and ELISA {#s4-9}
--------------------------

Western blotting was performed on the lysates of DRG neuron culture and tibial subchondral bone marrow. The samples were separated by SDS-PAGE gel and transferred onto a nitrocellulose membrane (Bio-Rad Laboratories). After incubation with specific primary and secondary antibodies, signals were detected by an enhanced chemiluminescence kit (Amersham Biosciences). The primary antibodies used are as follow rabbit anti-Na~V~1.8 (1:500, ASC-016, Alomone), rabbit anti-CREB (1:2000, \#9179, Cell Signaling Technology), rabbit anti-pCREB (1:1000, 9198, Cell Signaling Technology), rabbit anti-PKA c- **c-α** (1:1000, 4782, Cell Signaling Technology) and rabbit anti-GAPDH (1:1000, 5174, Cell Signaling Technology). The experiments were repeated three times and a representative film was selected.

To measure the concentration of PGE2 in the subchondral bone marrow of mice tibiae, a PGE2 ELISA kit (514010, Cayman) was used according to the manufacturer's manual. Briefly, we harvest the subchondral bone and then homogenized by ultrasound. The supernatant was aspired after high-speed centrifugation (13,200 g) for 10 mins. The concentration of PGE2 was normalized by total protein concentration using the BCA assay.

ChIP assay {#s4-10}
----------

The ChIP assay was carried out using the epiquik ChIP Kit (Epigentek catalog number: P-2002--1). Briefly, the cultured lumbar DRG cells were crosslinked with 1% formaldehyde at for 10 min. After the collection of the cell, the sonication was performed until the DNA was broken into fragments with a mean length of 200 bps -- 500 bps. The samples were subjected to immunoprecipitation with 2 mg of rabbit antibodies against pCreb1 (CST, 1:50) for 90 min at room temperature and 10% of the sample for immunoprecipitation was used as an input (a positive control). After purification, the DNA fragments were amplified using qRT-PCR with the primers for Na~V~1.8 promoter listed in Supplementary Table 2.

Retrograde tracing {#s4-11}
------------------

Retrograde tracing was performed at 3-month-old male SD rats (Charles River Laboratories) (300--400 g, n = 6 per group) 2 months after ACLT. According to the previous study ([@bib22]), a 20 mm parapatellar incision was made over the medial side of the left knee. Ipsilateral femoral and tibial subchondral bone were subject to retrograde labeling. We injected 2 μl DiI (Molecular Probes; with 5 mg/ml in N, N dimethylformamide) into the femoral and tibial subchondral bone areas using a Hamilton syringe with a 27-gauge needle. Immediately after injection, bone wax was used to seal the drilling holes to prevent tracer leakage. Animals were euthanized 2 weeks after retrograde injection and the left lumbar DRGs (L3-5) were isolated for fluorescence detection. Twenty sections from each DRG were used for statistical analysis.

Statistical analysis {#s4-12}
--------------------

Data are presented as means ± standard deviations. Error bars represent standard deviations. We used unpaired or paired two-tailed Student's t-tests for comparisons between two groups, and one-way ANOVA with Bonferroni post hoc test for multiple comparisons, in comparison between three or more groups, two-way ANOVA with Bonferroni post hoc test were used. All data demonstrated a normal distribution and similar variation between groups. For all experiments, p\<0.05 was considered to be significant.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The manuscript provides compelling new evidence to support the conclusion that subchondral bone marrow resorption is related to osteoarthritis (OA) pain. Specifically, the authors nicely link prostaglandin production by osteoblasts to the activation of the sodium channel Na~V~1.8. This is seen as a very active area of investigation with strong clinical relevance.

**Decision letter after peer review:**

Thank you for submitting your article \"Aberrant subchondral osteoblastic metabolism modifies Na~V~1.8 for osteoarthritis\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Clifford Rosen as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and we have drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus, the revisions requested below only address clarity and presentation.

Summary:

The reviewers believe that the study is well done with appropriate controls and provides a clear conclusion consistent with the data. The implications extend beyond bone pathophysiology into the interaction between nervous system and bone metabolism in general terms and could initiate novel therapeutic approaches. Nevertheless, several issues need to be addressed to further strengthen the manuscript.

Revisions:

1\) The authors claim that osteoblast are central to inducing OA pain by secreting excessive PGE2, which is clearly novel and interesting. A question remains whether osteoclasts are also involved in inducing OA pain and, if so, what might be the mechanism?

2\) Na~v~1.8 is an important ion channel for chronic pain sensation. Could a Na~v~1.8 inhibitor be effective for OA pain treatment and disease progression? Please expound on this concept.

3\) The authors developed a bone targeting conjugate drug for OA disease control based on the aberrant osteoblastic function in OA. How is this conjugate linked to osteoblast metabolism and Na~v~1.8 function? Please describe the drug target and working mechanistic hypothesis.

4\) The relationship between OA pain and disease progression remains unclear, as noted by the authors. The anti-NGF antibody tanezumab shows efficacy in OA pain, even while certain patients suffer a rapid progression of joint degeneration after tanezumab therapy. The authors are encouraged to offer plausible explanations regarding this apparent clinical dissociation.

5\) The authors stated: \"Human genetic mutations of Na~V~1.8 directly induce pain hypersensitivity\". The authors should make clear that the mutation identified in the promoter region of the human *Scn10a* gene (encoding for Na~v~1.8) is the gain-of-function mutation.

6\) The authors need to justify why they chose ACLT OA model, instead of DMM OA model.

7\) In figure legends, the authors need to disclose if one-way or two-way ANOVA was used followed by the Bonferroni post hoc test. Some of the data involving two parameters need to use two-way ANOVA for statistical analysis. For example, Figure 1G involves different time points and different animal models, two-way ANOVA should be used.

8\) The authors do need to describe which statistical method was used following ANOVA in the figure legends.

9\) The authors need to provide more information on *Pirt-GCaMP3^fl/-^* mice.

10\) The authors have used the electronic Von Frey method to test behavior. Is there any evidence to support the choice of electronic Von Frey over manual Von Frey? Please specify if manual Von Frey was also used, and if any adjustments were made to distinguish true pain responses from \"touch-on\" responses and ambulation.

11\) The author developed a small molecule conjugate (Aln-Ly) but did not mention the injection method in the animal study -- please address this and expand on how the appropriate regime and dosage was planned since the toxicology of this conjugate is unknown.

12\) Please indicate how many graders evaluated the OA score in the Materials and methods section.
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Author response

> Revisions:
>
> 1\) The authors claim that osteoblast are central to inducing OA pain by secreting excessive PGE2, which is clearly novel and interesting. A question remains whether osteoclasts are also involved in inducing OA pain and, if so, what might be the mechanism?

We highly appreciate the positive comments from the reviewers. We agree that osteoblastic PGE2 plays a central role in inducing chronic OA pain during disease progression. Nevertheless, osteoclast also actively participate in OA progression and chronic hypersensitivity induction. As we know that osteoclasts and osteoblasts cooperate in bone metabolism. Our previous work demonstrated that subchondral osteoclasts induce OA progression through TGF-β pathway^\[1\]^. Moreover, osteoclasts secret axon guidance molecule Netrin-1 to induce sensory nerve innervation in subchondral bone area to induce OA pain hypersensitivity^\[2\]^. Collectively, we believe that osteoclast and osteoblast cooperatively participate in OA pain induction during aberrant subchondral bone metabolism through secreting a cascade of biologically active molecules.

> 2\) Na~v~1.8 is an important ion channel for chronic pain sensation. Could a Na~v~1.8 inhibitor be effective for OA pain treatment and disease progression? Please expound on this concept.

Na~v~1.8 is the most important voltage gated sodium channel in mechanical pain sensation. As OA pain is mainly mechanical hypersensitivity, we believe that the effectiveness of Na~v~1.8 inhibitor could be at least in two parts: the short term and long term. In the short term, Na~v~1.8 inhibitors could directly block action potential initiation in peripheral sensory nerve endings in subchondral bone area. In the long term, Na~v~1.8 inhibitors attenuate the chronic hypersensitivity which in turn could tunedown the local inflammatory environment as a feedback. In this sense, Na~v~1.8 inhibitors could be highly effective in OA pain management.

> 3\) The authors developed a bone targeting conjugate drug for OA disease control based on the aberrant osteoblastic function in OA. How is this conjugate linked to osteoblast metabolism and Na~v~1.8 function? Please describe the drug target and working mechanistic hypothesis.

The conjugate consists of two basic elements: the bone targeting alendronate and the TGF-β inhibitor. We link these two elements through hydroxyl group bond which could break as the conjugate reaches the bone surface. Since TGF-β is the upstream of aberrant bone metabolism in OA subchondral bone^\[1\]^, this conjugate could effectively rebalance the overactivated osteoblastic bone metabolism in subchondral bone area. As overactivated osteoblastic metabolism is blocked in subchondral bone, the local PGE2 level is reduced and Na~v~1.8 modification could be halted. Thus, the alendronate TGF-β conjugate could be therapeutically effective for OA pain management and disease progression by targeting the most upstream signals in bone metabolism.
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4\) The relationship between OA pain and disease progression remains unclear, as noted by the authors. The anti-NGF antibody tanezumab shows efficacy in OA pain, even while certain patients suffer a rapid progression of joint degeneration after tanezumab therapy. The authors are encouraged to offer plausible explanations regarding this apparent clinical dissociation.We are also highly interested in the side effect of this anti-NGF antibody tanezumab^\[3\]^. The most up to date clinical outcome of tanezumab shows that certain percentage of the patients suffered a rapid progression of the disease after drug administration. A number of theories have been proposed to explain the incidence of advanced arthropathies in this setting, the most common being that improved analgesia leads to increased loading of a diseased joint, resulting in disease progression. This phenomenon could be similar to neuropathic arthropathy (Charcot joint), which occurs secondary to loss of sensation in an extremity and can result in joint dislocations, fractures and fragmentation. However, there might be another biological explanation. NGF levels are high in inflammatory tissues, and these tissues have a high number of monocytes. NGF is reportedly part of an important regulatory pathway in monocytes and other cell types. Inflammatory stimuli activate Toll-like receptors (TLRs) on monocytes, which increases expression of the NGF receptor TrkA. Monocyte could also increase NGF production, and NGF signaling might abate TLR2-mediated cell death, broadening the beneficial effects ofNGF. In summary, NGF inhibitors can markedly reduce chronic musculoskeletal pain, but enthusiasm for these compounds has been dampened by a small number of cases of advanced arthropathy in OA joints. In this sense, novel drug targets of upstream signals in OA pain pathways are needed for a more comprehensive therapeutic approach.

> 5\) The authors stated: \"Human genetic mutations of Na~V~1.8 directly induce pain hypersensitivity\". The authors should make clear that the mutation identified in the promoter region of the human Scn10a gene (encoding for Na~v~1.8) is the gain-of-function mutation.

Thanks for the reviewers' suggestion. We have changed the word "mutation" to "gain of function mutation in the promoter region" in main text.

> 6\) The authors need to justify why they chose ACLT OA model, instead of DMM OA model.

ACLT and DMM are the common surgical OA models and they are applicable in some different scenarios. In ACLT models, disease progression is more rapidly with relatively high pain sensitivity which gives us a good opportunity to investigate pain mechanisms and therapies. Subchondral bone erosion of the posterior tibial plateau (in some cases reaching the growth plate) was demonstrated in histologic photomicrographs from the ACLT with more severe subchondral bone metabolism changes. Meanwhile, DMM model was commonly used in slowly progressing studies like cartilage destructions. In our previous study^\[2\]^, we compared this two models in OA pain induction and found no significant differences between this two models. As a result, we continue to use ACLT model in this study.

> 7\) In figure legends, the authors need to disclose if one-way or two-way ANOVA was used followed by the Bonferroni post hoc test. Some of the data involving two parameters need to use two-way ANOVA for statistical analysis. For example, Figure 1G involves different time points and different animal models, two-way ANOVA should be used.

Thanks for the reviewer's comment on statistical analysis. We added the 2-way ANOVA statistical analysis in the Materials and method section.

> 8\) The authors do need to describe which statistical method was used following ANOVA in the figure legends.

Thanks for the advice on statistical methods. We added ANOVA with Bonferroni post hoc test in all the figure legends as the Materials and methods section mentioned.

> 9\) The authors need to provide more information on Pirt-GCaMP3^fl/-^ mice.

*Pirt-GCaMP3^fl/-^* mice was developed in Dr Xinzhong Dong's lab^\[4-6\]^. In order to monitor the activity of large populations of DRG neurons in intact live animals, they developed an in vivo imaging technique using Pirt-GCaMP3 mice, in which the genetic-encoded Ca^2+^indicator GCaMP3 is specifically expressed in \>95% of all DRG neurons under the control of the Pirt promoter. We added the genetic background and functions of this mice in Materials and methods section.

> 10\) The authors have used the electronic Von Frey method to test behavior. Is there any evidence to support the choice of electronic Von Frey over manual Von Frey? Please specify if manual Von Frey was also used, and if any adjustments were made to distinguish true pain responses from \"touch-on\" responses and ambulation.

Thanks for the reviewer's interests on the electronic Von Frey test. We highly agree that considerable variance exits between groups in Von Frey tests. For this reason, we take the average numbers by two independent technicians and repeated the experiment by 3 times by the same standards. True response is more like a rapid withdrawal of the paw instantaneously after stimulation which could be differentiated from touch on and ambulation response. The reasons why we think electronic Von Frey may be more applicable are as follows:

1\) The direct force is used, and we do not need to calculate the paw withdrawal threshold.

2\) The force is more accurate than manual Von Frey meter.

3\) Electronic Von Frey could be easy to adjust the force. But manual Von Frey meters are very easy to be bend and not accurate.

> 11\) The author developed a small molecule conjugate (Aln-Ly) but did not mention the injection method in the animal study -- please address this and expand on how the appropriate regime and dosage was planned since the toxicology of this conjugate is unknown.

Thanks for the reviewer's concern on injection method. For conjugate injections, we used intraperitoneal injection method and 1mg/kg per week dosage according to previous toxicological experiments.

> 12\) Please indicate how many graders evaluated the OA score in the Materials and methods section.

The OARSI scores were evaluated by two independent graders and the averages were taken. We added this information in the Materials and methods section.
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